Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Cost Plus Drugs vs Lumora

Cost Plus Drugs
Graded #371

Lower grade

vs+7.599999999999994
Lumora
Graded #206

Higher grade

The verdict

Lumora takes it — 66.1/100 to 58.5/100.

Lumora grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lumora (Blue Skies MD LLC dba Lumora MD) is a physician-founded telehealth platform offering compounded semaglutide and tirzepatide in injectable and sublingual forms.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCost Plus Drugs +9
45
36
Dose & formulationLumora +10
65
75
Clinical oversightLumora +20
67
87
Labs & monitoringLumora +25
51
76
FulfillmentLumora +1
73
74
Contract termsEven
55
55
Cost Plus Drugs · left barLumora · right bar

The numbers

MetricCost Plus DrugsLumora
WeighScore58.5/10066.1/100
GradeCC
Scorecard rank#371#206
Semaglutide$279/mo (brand Ozempic)$199/mo (starting dose, plus a separate fee, compounded)
TirzepatideNot disclosed$299/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyYes
Cost Plus Drugs

Graded #371 · C

Strengths

  • Transparent pricing: wholesale cost + 15% markup + $5 pharmacy fee, the same for everyone
  • Around $279/mo for branded Ozempic — well below typical retail list prices
  • Mark Cuban's PBM-disrupting pharmacy, praised by Forbes Health, Wired, and KFF Health News
  • Ships to all 50 states; genuine FDA-approved Novo Nordisk Ozempic, not compounded
  • Partnered with 9amHealth so you can get prescribed and fill at Cost Plus pricing

Where it loses points

  • Fulfillment only — no telehealth intake; you need a prescription from an outside clinician
  • Ozempic is FDA-indicated for type 2 diabetes, not weight management — weight-loss use is off-label
  • Wegovy availability has been spotty — check current stock before assuming it ships
  • No compounded semaglutide or tirzepatide — brand only
  • No clinical follow-up — side-effect monitoring falls to your prescribing clinician
Lumora

Graded #206 · C

Strengths

  • Compounded semaglutide (5 dose tiers) and tirzepatide (6 dose tiers) in injectable and sublingual forms
  • Physician-founded by board-certified Drs. Sean and Shannon Arora (Arora Health & Aesthetics); clinician reviews every assessment
  • LegitScript certified, HIPAA compliant, medications dispensed through licensed U.S. pharmacy partners
  • Visit fees, medication, labs, and follow-up all included; full pricing shown before commitment
  • Peptide therapies offered including NAD+, sermorelin, glutathione, gonadorelin, and PT-141

Where it loses points

  • Pricing is fully gated behind the assessment — no public pricing; actual monthly costs unverifiable without completing intake
  • Compounded medications are not FDA-approved; compounding pharmacy partners not publicly named
  • Newer brand with 2026 founding; no Trustpilot rating or accessible public patient reviews found
  • No dietitian, coaching, or HSA/FSA eligibility disclosed on public pages
  • Claims all 50 states but 'treatment options may vary by state' with no explicit state-by-state coverage list

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard